Harbor Capital Advisors Inc. Reduces Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Harbor Capital Advisors Inc. cut its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,001,388 shares of the company’s stock after selling 26,350 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.68% of MiMedx Group worth $9,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of MDXG. Millennium Management LLC grew its position in shares of MiMedx Group by 339.9% in the 2nd quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock worth $6,164,000 after buying an additional 687,267 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in MiMedx Group by 47.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after acquiring an additional 413,443 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in MiMedx Group by 6.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after acquiring an additional 258,700 shares in the last quarter. JPMorgan Chase & Co. increased its position in MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after purchasing an additional 215,995 shares during the period. Finally, Jane Street Group LLC raised its holdings in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after purchasing an additional 174,797 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group currently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Stock Down 2.6 %

MiMedx Group stock traded down $0.23 on Friday, hitting $8.62. 138,083 shares of the stock traded hands, compared to its average volume of 701,786. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $8.95 and its 200 day simple moving average is $7.31. The firm has a market cap of $1.27 billion, a P/E ratio of 15.67 and a beta of 1.96.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.